Studi Penggunaan Lopinavir/Ritonavir Pada Pasien Covid-19 Derajat Ringan-Sedang Dengan Komorbid Hipertensi Dan Diabetes Melitus Di Rumah Sakit Bhayangkara H.S Samsoeri Mertojoso Surabaya

• Main Author: Muhammad Nashrullah, '-
• Format: Theses and Dissertations NonPeerReviewed
• Language: Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Japanese; Indonesian
• Published: 2021
• Subjects: RS1-441 Pharmacy and materia medica
• Online Access: https://repository.unair.ac.id/112387/1/1%20HALAMAN%20SAMPUL.pdf; https://repository.unair.ac.id/112387/2/2%20ABSTRACT.pdf; https://repository.unair.ac.id/112387/3/3%20DAFTAR%20ISI.pdf; https://repository.unair.ac.id/112387/4/4%20BAB%20I%20PENDAHULUAN.pdf; https://repository.unair.ac.id/112387/5/5%20BAB%20II%20TINJAUAN%20PUSTAKA.pdf; https://repository.unair.ac.id/112387/6/6%20BAB%20III%20KERANGKA%20KONSEPTUAL.pdf; https://repository.unair.ac.id/112387/7/7%20BAB%20IV%20METODE%20PENELITIAN.pdf; https://repository.unair.ac.id/112387/8/8%20BAB%20V%20HASIL%20PENELITIAN%20DAN%20PEMBAHASAN.pdf; https://repository.unair.ac.id/112387/9/9%20BAB%20VI%20KESIMPULAN.pdf; https://repository.unair.ac.id/112387/10/10%20DAFTAR%20PUSTAKA.pdf; https://repository.unair.ac.id/112387/11/11%20LAMPIRAN.pdf; https://repository.unair.ac.id/112387/12/KESEDIAAN%20PUBLIKASI.pdf; https://repository.unair.ac.id/112387/; http://www.lib.unair.ac.id
• Institution: Universitas Airlangga

Lopinavir/Ritonavir is proposed as one of the therapy for Covid-19 patients based on the ability to reduce viral load. Bhayangkara Hospital Surabaya is one of the hospitals with quite a lot of Covid-19 patients in Surabaya. The purpose of this study was to determine the effectiveness, outcome, and evaluate side effects of Lopinavir/Ritonavir in mild-moderate Covid-19 patients with comorbid hypertension and diabetes mellitus at Bhayangkara Hospital Surabaya. This type of research isobservational with retrospective data collection on patient medical record samples during the period June 2020-February 2021. The results showed that 7 patients (39%) received therapy A with 11 days of treatment, 4 patients received therapy B (22%) with 12 days of treatment, 1 patient (11%) received therapy C with 18 days of treatment, and 6 patients (28%) on D therapy with 14 days of treatment. Patients experiencing effects of gastrointestinal disturbances such as nausea (22%), and diarrhea (11%). The conclusion of this study is that Lopinavir/Ritonavir (2 x 400 mg/100 mg) in therapy A is the most effective when viewed from the length of treatment, which is 11 days. Therapy B, C, and D were considered effective as seen from the results of RT-PCR which showed negative results, namely 100%. Therapy D is the most effective of chest X-ray repair, which is 50%. The side effects found were gastrointestinal disturbances, namely nausea (22%), diarrhea (11%), while hepatotoxicity was not found.